8WK.F ABERA BIOSCIENCE AB
- Market cap
- EUR 13.0M
- P/E
- -
- P/B
- 8.01x
- ROE
- -126.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 8WK.F undervalued?
Graham numberThe Graham number of ABERA BIOSCIENCE AB cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ABERA BIOSCIENCE AB fundamental analysis
No fundamental analysis for ABERA BIOSCIENCE AB yet.
ABERA BIOSCIENCE AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ABERA BIOSCIENCE AB
Abera Bioscience AB (publ), a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETE…
Full company profileABERA BIOSCIENCE AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ABERA BIOSCIENCE AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -19.5M | -16.9M | -1.34M | -10.6M | -22.9M |
| EBITDA | -19.4M | -16.7M | -1.04M | -10.3M | -22.5M |
| Net Income | -19.4M | -16.7M | -1.10M | -10.5M | -22.7M |
| EPS | -1.50 | -1.16 | -0.07 | -0.56 | -1.11 |
| Balance Sheet | |||||
| Total Assets | 19.6M | 9.35M | 13.6M | 28.6M | 22.5M |
| Total Liabilities | 2.80M | 3.69M | 4.95M | 9.28M | 4.55M |
| Shareholders' Equity | 16.8M | 5.66M | 8.66M | 19.3M | 17.9M |
| Cash & Short-term Investments | 15.4M | 3.32M | 6.09M | 23.5M | 17.7M |
| Cash Flow | |||||
| Operating Cash Flow | -19.7M | -17.7M | -198K | -3.26M | -31.6M |
| Capital Expenditure | 0.00 | 0.00 | 1.13M | 426K | 0.00 |
| Free Cash Flow | -19.7M | -17.7M | -1.33M | -3.68M | -31.6M |
| Ratios | |||||
| ROE | -115.5% | -295.7% | -12.7% | -54.2% | -126.7% |
| ROA | -99.0% | -178.9% | -8.1% | -36.6% | -101.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
ABERA BIOSCIENCE AB dividends
ABERA BIOSCIENCE AB has not paid dividends in the last 5 fiscal years.
Who owns ABERA BIOSCIENCE AB
Ownership data of ABERA BIOSCIENCE AB is not available yet.
ABERA BIOSCIENCE AB company profile
- Company name
- ABERA BIOSCIENCE AB
- Ticker
- 8WK.F
- ISIN
- SE0015245097
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- Virdings allé 32, Uppsala, Sweden, 754 50
- Website
- aberabio.com
About ABERA BIOSCIENCE AB
Abera Bioscience AB (publ), a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is headquartered in Uppsala, Sweden.
ABERA BIOSCIENCE AB management
4- Mr. Anders EricssonExecutive Chairman of Board · born 1970
- Ms. Maria AlrikssonChief Executive Officer · born 1983
- Associate Prof. Joen LuirinkCo-Founder & CTO · born 1960
- Mr. Mats LundgrenVP of Research & Development and CSO · born 1963